We observe that TIMP1 expression is statistically significantly downregulated in samples from MM patients with a favorable prognosis (p < 0.05), which is consistent with the data published previously, confirming the feasibility of using TIMP1 as a prognostic biomarker in MM. The gene discussed is TIMP1; the disease is Miyoshi myopathy.